Literature DB >> 21243406

A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.

Xingchen Peng1, Fengming Gong, Gang Xie, Yuwei Zhao, Minghai Tang, Luoting Yu, Aiping Tong.   

Abstract

This study aimed to explore the mechanism of adriamycin resistance in human chronic myelogenous leukemia cells. Proteomic approach was utilized to compare and identify differentially expressed proteins between human chronic myelogenous leukemia K562 cells and their adriamycin-resistant counterparts. The differentially expressed proteins were analyzed by 2-DE (two-dimensional gel electrophoresis), and protein identification were performed on ESI-Q-TOF MS/MS instrument. Out of the 35 differentially expressed proteins between the two cell lines, 29 were identified and grouped into 10 functional classes. Most of identified proteins were related to the categories of metabolism (24%), proteolysis (13%), signal transduction (21%) and calcium ion binding (6%), suggesting that alterations of those biological processes might be involved in adriamycin resistance of K562 cells. We believe this study may provide some clues to a better understanding of the molecular mechanisms underlying adriamycin resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21243406     DOI: 10.1007/s11010-011-0730-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

Review 1.  A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways.

Authors:  T Maniatis
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

2.  Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins.

Authors:  Y Fukumoto; K Kaibuchi; Y Hori; H Fujioka; S Araki; T Ueda; A Kikuchi; Y Takai
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

Review 3.  Proteomic technologies and their application to pancreatic cancer.

Authors:  Dale Vimalachandran; Eithne Costello
Journal:  Expert Rev Proteomics       Date:  2004-12       Impact factor: 3.940

4.  Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines.

Authors:  Marzia B Gariboldi; Raffaella Ravizza; Loredana Riganti; Stefania Meschini; Annarica Calcabrini; Manuela Marra; Giuseppe Arancia; Ersilia Dolfini; Elena Monti
Journal:  Int J Oncol       Date:  2003-05       Impact factor: 5.650

Review 5.  Study of therapy resistance in cancer cells with functional proteome analysis.

Authors:  Julia Poland; Dirk Schadendorf; Hermann Lage; Martina Schnölzer; Julio E Celis; Pranav Sinha
Journal:  Clin Chem Lab Med       Date:  2002-03       Impact factor: 3.694

Review 6.  Proteomic profiling of pancreatic cancer for biomarker discovery.

Authors:  Ru Chen; Sheng Pan; Teresa A Brentnall; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2005-01-31       Impact factor: 5.911

Review 7.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

Authors:  J M Brown
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

8.  Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells.

Authors:  Fei Zhang; Lin Zhang; Bin Zhang; Xiyin Wei; Yi Yang; Robert Z Qi; Guoguang Ying; Ning Zhang; Ruifang Niu
Journal:  J Proteome Res       Date:  2009-11       Impact factor: 4.466

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 10.  The proteasome as a target for cancer therapy.

Authors:  Peter M Voorhees; E Claire Dees; Bert O'Neil; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  4 in total

1.  Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.

Authors:  Dehuan Ji; Pengshan Zhang; Wenjuan Ma; Yiwen Fei; Wen Xue; Yu Wang; Xiuyan Zhang; Haixia Zhou; Yun Zhao
Journal:  Oncogene       Date:  2019-09-05       Impact factor: 9.867

2.  Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Authors:  S Sun; X Liang; X Zhang; T Liu; Q Shi; Y Song; Y Jiang; H Wu; Y Jiang; X Lu; D Pang
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

3.  Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

Authors:  Yanling Fan; Weiyao Si; Wei Ji; Zhiyong Wang; Zicong Gao; Ran Tian; Weijie Song; He Zhang; Ruifang Niu; Fei Zhang
Journal:  Breast Cancer Res       Date:  2019-05-22       Impact factor: 6.466

4.  Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Authors:  Maria Rosaria Ricciardi; Valentina Salvestrini; Roberto Licchetta; Simone Mirabilii; Mattia Forcato; Gabriele Gugliotta; Simona Salati; Fausto Castagnetti; Gianantonio Rosti; Massimo Breccia; Giuliana Alimena; Rossella Manfredini; Silvio Bicciato; Roberto Massimo Lemoli; Agostino Tafuri
Journal:  Oncotarget       Date:  2018-04-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.